Selonterra Awarded $2.5 Million Grant From The Michael J. Fox Foundation To Develop Genetic Therapies For Parkinson’s Disease

The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded Selonterra—a biotechnology company developing transformative therapies for neurodegenerative disorders with genetic causes—a $2.5 million grant to support their Parkinson's small molecule research in a continued effort to find a cure for the disease.

"MJFF greatly values research that takes fresh looks at the biological underpinnings of Parkinson's disease and leverages that insight for new treatment ideas. We are proud to support the work of researchers like the team at Selonterra as they investigate new ways to fulfill the unmet needs of people with Parkinson . . .